ArticleBMJ open2026

Pembrolizumab plus lenvatinib in the treatment of unresectable cutaneous angiosarcoma: a study protocol of multicentre, open-label phase II study (NCCH2213, PLAS).

Dai Ogata et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.